MLchartDataset catalogue

Imgatuzumab

Term · Oncology and biomedicine · MLC-T-ONC-014371

A glycoengineered monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Imgatuzumab binds to the extracellular domain of EGFR, preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition of downstream ERK and JNK signaling pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various solid tumor cell types.

Table 1. Record
IdentifierMLC-T-ONC-014371
FieldOncology and biomedicine
Synonymsanti-epidermal growth factor receptor monoclonal antibody RO5083945
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014371",
  "term": "Imgatuzumab",
  "field": "Oncology and biomedicine",
  "definition": "A glycoengineered monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Imgatuzumab binds to the extracellular domain of EGFR, preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition of downstream ERK and JNK signaling pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various solid tumor cell types.",
  "synonyms": [
    "anti-epidermal growth factor receptor monoclonal antibody RO5083945"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/imgatuzumab/"
}

Record 9,048 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.